A study led by scientists at NYU Langone Health sheds light on how the major cancer gene BRCA2 determines which cancer cells can be killed by a class of precision cancer drugs called PARP inhibitors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback